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Background: Platelet inhibitors are commonly used to reduce the risk of atherothrombotic events. The aim of this
study was to determine the impact of platelet inhibitors, specifically clopidogrel and aspirin, on clot kinetics,
strength, and/or structure during the use of thrombin based gelatin matrices and fibrin sealants.
Methods: Blood was collected and heparinized from donors on clopidogrel (and aspirin) and age matched control
donors. Blood component analysis, whole blood platelet aggregometry, and activated clotting time (ACT) were
used to monitor compliance to therapy and identify any differences between donor groups. Clot kinetics and
strength were analyzed using thrombelastography (TEG). Field Emission Scanning Electron Microscopy (FESEM) was
used to analyze clot structure.
Results: Blood component profiles were similar for both donor groups. Aggregometry indicated that aggregation
response to adenosine diphosphate (ADP) for clopidogrel donors was 12% of that for the controls (p = 0.0021), an
expected result of clopidogrel induced platelet inhibition. However, blood from both donor groups had an
elevated thrombin induced aggregation response. Heparinization of donor blood resulted in similarly elevated ACTs
for both donor groups. TEG results indicated similar clot kinetics and strength between clopidogrel and control
donor groups for blood alone and when clotting was induced using thrombin based gelatin matrices and fibrin
sealants. FESEM images supported TEG findings in that similar morphologies were observed in ex vivo formed clots
from both donor groups when thrombin based gelatin matrices and fibrin sealants were used.
Conclusion: These results suggest that platelet inhibitors do not negatively impact clot kinetics, strength, and
structure when clotting is initiated with thrombin based gelatin matrices and fibrin sealants.
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Platelets contribute to physiological hemostasis by aggre-
gating at the site of a lesion, providing surfaces for
hemostatic reactions, and supplying regulatory hemostatic
factors. They also contribute to atherosclerotic disease by
stimulating and stabilizing thrombi. Following myocardial
infarction or stroke, the American Heart Association and
American College of Cardiology guidelines recommend
that patients take platelet inhibitors to reduce the risk of* Correspondence: joseph-dwyer@sbcglobal.net
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unless otherwise stated.further atherothrombotic events [1,2]. Clopidogrel and as-
pirin (acetylsalicylic acid) are commonly used platelet in-
hibitors. Both drugs reduce mortality in patients with
chronic atherosclerotic disease and are also effective drugs
for the acute treatment of infarcts [3].
Platelet aggregation is disrupted by these inhibitors via
two distinct pathways. Clopidogrel acts as an inhibitor of
adenosine diphosphate (ADP) induced platelet aggrega-
tion by covalently binding to its receptor, P2Y12. ADP
mediated activation of the GPIIb/IIIa complex is there-
fore abated [4-6]. Aspirin irreversibly inhibits cyclooxy-
genase enzymes, COX1 and COX2 [7]. This prevents
the conversion of arachidonic acid to thromboxane A2Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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gation [8,9]. Clopidogrel and aspirin can be used indi-
vidually or in combination for dual anti-platelet therapy.
Several clinical studies have linked the use of platelet ac-
tivation inhibitors to increased bleeding during surgery
resulting in excess blood loss, increased transfusion rates,
and reoperation [10-13]. These findings led the authors of
these studies to recommend that surgery be delayed if
possible to allow patients to withdraw from anti-platelet
therapy [10,12]. Clopidogrel and aspirin both irreversibly
alter platelet function. As a result, platelet aggregation and
bleeding time generally do not return to normal levels
until 5 days after discontinuing usage when sufficient
quantities of new unaffected platelets have been produced
[14]. Recommendations for and optimal time interval be-
tween cessation of anti-platelet medications and surgery
vary from 3–10 days [15-18].
Other studies have suggested that the risk of further
atherothrombotic events outweighs the risk of increased
bleeding during surgery and recommend that in certain
situations patients remain on either aspirin or dual anti-
platelet therapy throughout the perioperative period
[19,20]. For example, patients who are at an intermediate
or high risk for cerebro- or cardiovascular events are rec-
ommended to remain on both clopidogrel and aspirin
during many types of surgeries such as orthopedic surgery,
reconstructive surgery, and endoscopy [19]. Consequently,
many patients are undergoing surgical procedures with
significant platelet inhibition as a result of a reluctance or
inability (i.e. non-elective/emergency procedures) to with-
hold anti-platelet therapy prior to surgery. In such cases,
surgeons face concerns that adjunctive thrombin based
gelatin matrix and fibrin sealant hemostatic agents may
not work effectively for patients on anti-platelet therapy.
Gelatin matrices and fibrin sealants that contain a
thrombin component have been used for many years as
effective adjunctive hemostats in surgery [21,22]. Both ex-
ogenous hemostats stop bleeding by inducing physio-
logical hemostasis in a number of distinct ways. They
curtail bleeding on tissue surfaces by generating fibrin me-
diated blood clots. As thrombin based gelatin matrices
rely on incoming blood to supply the substrates for
hemostatic clots, one potential clinical concern is that
these hemostats may not work effectively for patients tak-
ing platelet aggregation inhibitors such as clopidogrel and
aspirin. They also provide a high dose of thrombin, novel
topologies, and substrates for blood and tissue derived fac-
tors to regulate hemostasis, and, in the case of thrombin
based gelatin matrix hemostats, the gelatin particles pro-
vide a tamponade effect at the wound site, as well as con-
tact activation, which leads to platelet activation.
The purpose of this study was to evaluate clots formed
when thrombin based gelatin matrices and fibrin seal-
ants were mixed with heparinized blood from patientswho were taking clopidogrel to determine whether there
was a negative impact of this platelet activation inhibitor
on clot kinetics, strength, and/or structure. Assays
employing whole blood were selected where appropriate
for sample testing to more closely reflect the surgical
conditions during application of the hemostats. Clot
kinetics and strength were analyzed using thrombelas-
tography (TEG) and clot structure was analyzed using
Field Emission Scanning Electron Microscopy (FESEM).
TEG was deemed an appropriate assay since it uses
whole human blood, and it has been used to monitor
patient hemostasis profiles during cardiac and general
surgery [23,24].
Methods
Donor criteria and collection of whole blood
Donor samples were collected from individuals in ac-
cordance with Baxter Healthcare’s Internal Review Board.
Blood was collected from three donors on clopidogrel
and aspirin and one donor on only clopidogrel. Blood
was also taken from four age matched control donors
who were not taking clopidogrel or aspirin (i.e. con-
trol). The small number of donors is a consequence of
the limited available donor pool and selection criteria
(Table 1). These criteria were used isolate the impact of
clopidogrel on hemostat performance from other drugs
or medical conditions that interfere with hemostasis.
The first 2–3 ml of blood collected was discarded from
each donor. Thereafter, 25 ml of blood was collected in
sodium citrate (3.2%). An additional 5 ml aliquot was
collected in EDTA (1.5 mg/ml). The blood collected in
EDTA was used for analysis of the blood cells, platelets,
hematocrit, and hemoglobin. Other analyses were per-
formed using citrated blood. All researchers performing
the assays were blinded to donor status throughout the
course of the study.
Blood component analyses
To investigate possible non-pharmaceutical related differ-
ences between the donor groups, a series of blood ana-
lyses were performed. Red and white blood cells, platelets,
hemoglobin, and hematocrit were quantified for each
donor sample with an ADVIA 2120 Hematology Sys-
tem (Siemens Corporation; Malvern, PA) using an
aliquot of whole blood freshly collected in EDTA. The
remaining blood analyses were performed using plasma
prepared by centrifugation of citrated whole blood.
The plasma was stored at −80°C. Fibrinogen concentra-
tion was measured using a STA Compact Hemostasis
System (Diagnostica Stago; Parsippany, NJ), Factor VIII
activity was measured using a Behring Coagulation Sys-
tem (Siemens Corporation; Malvern, PA), and Factor
XIII levels were measured by ELISA (AssayPro; St.
Charles, MO).
Table 1 Inclusion and exclusion criteria for donors
Inclusion criteria for clopidogrel donors Inclusion criteria for age matched control donors Exclusion criteria
Clopidogrel or clopidogrel and aspirin use
for at least 14 days prior to blood draw
No clopidogrel use for at least 14 days
prior to blood draw
History of diabetes, renal failure, acute or
chronic liver disease, including acute or
chronic hepatitis or cirrhosis
If on aspirin, daily aspirin dosage of at
least 75 mg/day
No aspirin use for at least 14 days prior
to blood draw
Positive for HIV, hepatitis B, or hepatitis C
Males and Females Males and Females Use of Selective Serotonin Re-uptake
Inhibitors (SSRIs), Seritonin-Norepinepherin
Re-uptake Inhibitors (SNRIs), Omeprazole
(which interferes with clopidogrel
metabolism) [25], or oral anticoagulants
(Coumadin, Warfarin, etc.)
Table 2 Evaluated TEG coagulation parameters
Coagulation parameter Description
R-time (R) The time from the start of a sample run
until the first significant levels of
detectable clot formation in
minutes (min).
K-time (K) The time from the measurement of R
until a fixed level of clot firmness is
reached (Amplitude = 20 mm) in
minutes (min).
Angle (α) An indicator of the kinetics of clot
formation and fibrinogen level
quantified in degrees (º).
Maximum Amplitude (MA) A measurement of maximum
strength or stiffness of the developed
clot in millimeters (mm) and an
indicator of platelet function.
Shear Elastic Modulus
Strength (G)
A measurement of clot strength
calculated as G = (5000A/(100-A))/1000
and reported as dynes per square
centimeter (d/sc).
Time to MA (TMA) The time until the maximal clot strength
(MA) is reached in minutes (min).
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Platelet aggregation induced by either ADP (10 μM final
concentration, Chrono-Log Corporation; Havertown, PA.)
or Thrombin (1 IU/ml final concentration, Baxter Health-
care Corporation; Deerfield, IL) was assessed in citrated
whole blood on both clopidogrel and control donors.
A Model 560VS Dual Channel Whole Blood Lumi-
Aggregometer (Chrono-log; Havertown, PA) using an
impedance technique was used for testing each sample
in duplicate per agonist, with the duplicates being
averaged to obtain a final result.
Blood heparinization and activated clotting time (ACT)
Heparin (APP Pharmaceuticals, LLC; Schaumburg, IL)
was added to each citrated whole blood sample to
achieve a final concentration of 5 U/ml prior to TEG
and imaging in order to assess the blood under clinically
relevant heparin levels [26]. An Activated Clotting Time
(ACT) measurement was taken of each blood sample be-
fore and after adding heparin using a Hemochron Re-
sponse Whole Blood Coagulation System (International
Technidyne Corporation; Edison, NJ). Because citrated
blood was used for these measurements, calcium chlor-
ide was added to each test sample immediately prior to
ACT analysis to return calcium ion concentration to a




Clot kinetics and strength were measured using a Throm-
belastograph 5000 (Haemoscope Corporation; Niles, IL).
TEG measurements were taken from citrated whole
blood, heparinized blood, heparinized blood that was
mixed with a thrombin based gelatin matrix (Floseal VH
S/D: Baxter Healthcare Corporation; Deerfield, IL), and
heparinized blood mixed with fibrin sealant (Tisseel VH
S/D: Baxter Healthcare Corporation; Deerfield, IL). A
sufficient level of calcium ion to overcome the chelating
effect of sodium citrate was supplied by the thrombin
component of each hemostat which was reconstitutedin calcium chloride so no further calcium supplementa-
tion was needed. The clotting process as monitored by
the TEG is reported as a set of coagulation parameters
(Table 2).
TEG analysis with citrated and heparinized blood alone
The cup & pin were loaded onto the TEG. Calcium chlor-
ide solution (20 μl) was added to the cup. Citrated or hep-
arinized blood (340 μl) was then added to the cup, and the
TEG analysis was immediately initiated. Donor samples
were analyzed in triplicate.
Preparation of the thrombin based gelatin matrix for TEG
analysis
Floseal VH S/D is a bovine-derived gelatin matrix that is pre-
pared with human thrombin and indicated for hemostasis
when control of bleeding by ligature or conventional
procedures is ineffective or impractical [27]. Three lots
of thrombin based gelatin matrix were prepared per IFU
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(0.100 g or ~1/8 of a 5 ml kit syringe) was weighed out on
weigh paper and then back-loaded into a 1 ml tuberculin
syringe. To remove air, the granules were compressed to-
wards the luer end of the syringe. In a second tuberculin
syringe, 0.5 ml of 500 IU/ml thrombin solution was with-
drawn (prepared by adding 5 ml CaCl2 to the thrombin
vial) and a syringe connector was attached (luer end facing
up). The two syringes were connected (one with gelatin
and one with thrombin solution) and ‘swooshed’ at least 20
times to mix the gelatin and thrombin solution adequately.
TEG analysis with thrombin based gelatin matrix
The cup & pin were loaded onto the TEG. The cup was
subsequently removed from the TEG. The TEG cup was
placed on the scale and the weight was zeroed. The first
100 μl of mixed thrombin based gelatin matrix was dis-
carded from the syringe. The tip of the syringe was
cleaned with a Kimwipe to ensure that no excess throm-
bin based gelatin matrix remained. Using the tuberculin
syringe, 150 μl of the mixed thrombin based gelatinFigure 1 Blood component analyses results. The left panel shows dot-p
where blood parameters are indicated on the y-axis and the ratios of avera
CIs on the x-axis.matrix was placed at the bottom of the TEG cup. The
weight of the added thrombin based gelatin matrix was
recorded. If the weight was 0.1160 g to 0.1260 g, the
sample was used. If not, the weight was adjusted so that
the weight of sample in the cup was in this range. The
cup was impacted against the lab bench several times to
concentrate the thrombin based gelatin matrix evenly on
the bottom of the cup. Heparinized blood (210 μl) was
added to the cup and mixed quickly with the thrombin
based gelatin matrix using a pipette tip. The cup was
then loaded onto the TEG with analysis initiated imme-
diately. Donor samples were analyzed in triplicate with
each of the three lots of thrombin based gelatin matrix.
Preparation of the fibrin sealant for TEG analysis
Tisseel VH S/D is a human-derived fibrin sealant indicated
for hemostasis in surgeries involving cardiopulmonary by-
pass and treatment of splenic injuries due to blunt or pene-
trating trauma when control of bleeding by conventional
techniques is ineffective or impractical [28]. Three lots of fi-
brin sealant were prepared per IFU. The fibrinogen andlots of all blood parameters and group. The right panel shows a CI plot
ges (clopidogrel relative to control) and corresponding two-sided 95%
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40 mM CaCl2 was brought to room temperature. The fi-
brinogen was reconstituted in aprotinin (F.C. ~100 mg/ml).
The re-suspended fibrinogen was placed in a Fibrinotherm
(Baxter Healthcare Corporation; Deerfield, IL) until dis-
solved and stored at 37°C until used. The thrombin was
reconstituted in 40 mM CaCl2 (F.C. ~500 IU/ml) and
stored at room temperature until used.
TEG analysis with fibrin sealant
The cup & pin were loaded onto the TEG. The cup was
subsequently removed from the TEG. Heparinized blood
(210 μl) was added to the cup. Fibrinogen solution
(75 μl, ~7.5 mg) and thrombin solution (75 μl, ~37.5 IU)
were added to the TEG cup simultaneously in conjunc-
tion with the blood volume above to total 360 μl. The
sample was mixed quickly using a pipette tip and the
cup loaded into the TEG. TEG analysis was immediately
initiated. Donor samples were analyzed in triplicate with
each of the three lots of fibrin sealant.Figure 2 Whole blood aggregation results after activation with ADP o
aggregation impedance per group for aggregation induced with ADP and
is indicated on the y-axis and the ratios of averages (clopidogrel relative to
the x-axis. No bounded two-sided 95% CI for the ratio regarding ADP is av
statistically different from zero.Field emission scanning electron microscopy (FESEM)
Preparation of thrombin based gelatin matrix clots
The thrombin based gelatin matrix was prepared per
IFU as indicated above and 150 μl was dispensed into a
well of a 24 well plate. Heparinized blood (210 μl) was
added to the well and the blood and hemostat were
quickly mixed. The clot was allowed to set for 30 mi-
nutes at 37°C before the addition of 2 ml/well of phos-
phate buffered saline (PBS). Clots were subsequently
detached from the bottom of each well. After another
30 minutes at 37°C, the clot was rinsed with 1 ml PBS
and fixed overnight at 4°C in 2 ml of 2% glutaraldehyde
(Electron Microscopy Sciences; Hatfield, PA) in 0.1 M
HEPES buffer.
Preparation of fibrin sealant clots
The fibrinogen and thrombin components of the fibrin
sealant were prepared per IFU as indicated above. Hepa-
rinized blood (210 μl) was added to the well of a 24 well
plate followed by 75 μl of fibrinogen solution and 75 μlr thrombin. The left panel shows dot-plots of whole blood platelet
thrombin. The right panel shows a CI plot where the type of induction
control) and corresponding two-sided 95% CIs are presented on
ailable as the numerator of the ratio (i.e. mean of clopidrogel) is not
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quickly mixed and the clot was allowed to set for 30 mi-
nutes at 37°C. Two milliliters of PBS were added to the
well and the clot was detached from the bottom of the
well. After another 30 minutes at 37°C, the clot was
rinsed with 1 ml PBS and fixed overnight at 4°C in 2 ml
of 2% glutaraldehyde in 0.1 M HEPES buffer.
Preparation of clots for FESEM
After clot fixation, clots were rinsed with 0.1 M HEPES
buffer and dehydrated in a graded ethanol (EtOH) series
to 100% EtOH. The specimens were placed into 2:1, 1:1,
and 1:2 solutions of 100% EtOH to hexamethyldisilazane
(HMDS, Electron Microscopy Sciences; Hatfield, PA),
rinsed three times in 100% HMDS followed by a quick
change of 100% HMDS, and allowed to air dry. The speci-
mens were then mounted onto FESEM stubs affixed with
double-stick conductive carbon tape and sputter coated
with palladium in a Desk IV Sputter/Etch Unit (Denton
Vacuum; Moorestown, NJ). The samples were examined
in a JSM-6300 F FESEM (JEOL; Tokyo, Japan) and repre-
sentative areas were recorded as digital images.Figure 3 ACT results pre and post-heparinization. The left panel shows
post-heparinization. The right panel shows a CI plot for pre- and post-hepa
control) and corresponding two-sided 95% CIs are presented on the x-axisStatistical analyses
Comparison of clopidogrel versus control results was
considered to be exploratory; therefore, analysis focused
on estimation of group effects using confidence intervals
(CIs) rather than on hypothesis testing. All analyses were
performed with R version 2.15.3 (R Core Team; Vienna,
Austria) [29].
Blood analysis
Differences in blood parameters between clopidrogel
and control donors were assessed using ratios of aver-
ages, corresponding two-sided 95% CIs, and two-sided
p-values obtained by R function “t.test.ratio (option var.
equal = FALSE)” of R package “mratios” [30].
Thrombelastography
TEG data were analyzed using a linear mixed effects
model taking the replicate measurements per donor ad-
equately into account. The model consisted of the fixed
effect group (clopidogrel and control) and donor as
random effects, and was fitted using R function “lme”
of R package “nlme” [31]. Differences in TEG datadot-plots of activated clotting time per group and pre and
rinization (y-axis) where the ratios of averages (clopidogrel relative to
.
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using ratios of averages, corresponding two-sided 95%
CIs and two-sided p-values where the two-sided 95% CI




Four clopidogrel donors and four control donors that
met the set criteria were used for this study. The four
clopidogrel donors were taking clopidogrel daily and
three of the four donors were also taking daily aspirin.
The control donors had not taken clopidogrel or aspirin
for at least 14 days prior to blood collection. The median
age of clopidogrel and control donors was 55 (range: 47
to 62) and 55 (range: 50 to 58) years, respectively.
Blood component analyses
The results of the blood component analyses were
similar between donor groups (Figure 1). The largest dif-
ference between donor groups was observed in WBCFigure 4 TEG data: citrated blood. The left panel shows dot-plots of all T
where TEG parameters are indicated on the y-axis and the ratio of average
on the x-axis.with a 1.78 (95% CI: 0.83 to 2.82) times higher average
WBC count for clopidogrel donors than for control do-
nors; however, this difference was not statistically signifi-
cant at the 5% level.Whole blood platelet aggregometry
Average aggregation response to adenosine diphosphate
(ADP) for clopidogrel donors was 12% of that for the
controls (p = 0.0021) (Figure 2). However, when throm-
bin was used as the agonist on the same blood obtained
from the same donors, the platelet aggregation response
was normalized with a 1.08 (95% CI: 0.92 to 1.27) times
larger average response for clopidogrel donors.Activated clotting time (ACT)
The addition of heparin to the each donor’s blood re-
sulted in an expected increase in ACT (Figure 3). On
average, clopidogrel donors had a 1.23 (95% CI: 0.83 to
2.07) and 1.01 (95% CI: 0.62 to 1.97) times longer ACT
before and after addition of heparin, respectively.EG parameters per donor and group. The right panel shows a CI plot
s (clopidogrel relative to control) and corresponding two-sided 95% CIs
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Citrated and heparinized blood alone
TEG data for citrated blood (Figure 4) indicates that across
all TEG parameters there is a trend which suggests that
clopidogrel may impede hemostasis; however differences
between donor groups did not reveal statistical significance
at the 5% level for any of the parameters. Heparinized
blood alone samples did not clot for any donor and were
stopped after 45 minutes in the TEG (data not shown).
Thrombin based gelatin matrix and fibrin sealant
TEG parameter results for the thrombin based gelatin
matrix (Figure 5) and fibrin sealant (Figure 6) mixed
with donor blood were similar between donor groups
based on the ratios of averages.
FESEM of thrombin based gelatin matrix and fibrin
sealant clots
Images of thrombin based gelatin matrix clots (Figure 7)
from both donor groups appeared morphologically similar.Figure 5 TEG data: thrombin based gelatin matrix. The left panel show
shows a CI plot where TEG parameters are indicated on the y-axis and the
two-sided 95% CIs on the x-axis. Due to the rapid rate of clot formation wh
enough to generate values for R and K other than the lowest possible data
eters between donor groups.The fibrin structure had similar fiber thickness, branch-
ing, and porosity. Clots generated with the fibrin seal-
ant (Figure 8) also had similar morphology for both
donor groups.
Discussion
In this study, clopidogrel had no significant impact on
the kinetics and visco-elastic clot strength of whole
blood clots formed ex vivo. This result is consistent with
the relative low risk of bleeding observed in patients
taking clopidogrel [14]. Perhaps clopidogrel has a bigger
mechanistic impact on a plaque stimulated thrombus
than it has on disrupting physiological hemostasis
due to differences in temporal activation, sequence of
thrombin activation, or the relative greater importance
of platelets.
Blood component measurements indicated similar re-
sults between clopidogrel and control donors with the
exception of average WBC count which was 1.78 (95%
CI: 0.83 to 2.82) times higher for clopidogrel donorss dot-plots of all TEG parameters per donor and group. The right panel
ratio of averages (clopidogrel relative to control) and corresponding
en using the thrombin based gelatin matrix, the TEG is not sensitive
value for most sample replicates preventing comparison these param-
Figure 6 TEG data: fibrin sealant. The left panel shows dot-plots of all TEG parameters per donor and group. The right panel shows a CI plot
where TEG parameters are indicated on the y-axis and the ratio of averages (clopidogrel relative to control) and corresponding two-sided 95% CIs
on the x-axis. Due to the rapid rate of clot formation when using the fibrin sealant, the TEG is not sensitive enough to generate values for R other
than the lowest possible data value for most sample replicates preventing comparison this parameters between donor groups.
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of covariance of the difference in blood aggrega-
tion after activation with ADP and thrombin between
donor groups adjusted for potential differences in WBC
count resulted in two-sided p-values of p = 0.0046 and
p = 0.3908 respectively leading to the same statistical
conclusion as without using WBC count as a covariate
(Figure 2). The similarity in remaining blood parameter
measurements reduces the likelihood that a difference in
another coagulation factor or blood component influ-
enced aggregation response to adenosine diphosphate or
thrombin. The averages for ACT before and after addition
of heparin were similar between both donor groups. How-
ever, the addition of heparin to the blood samples did
elevate the clotting time to clinically relevant values.
The average clotting times for both donor groups were
between 550 and 600 seconds following addition of
heparin compared to averages below 200 seconds at base-
line. ACTs between 300 and 600 seconds are described
as the ‘safe zone’ for patients undergoing extracorporealcirculation [33] while the ACT for cardiac surgery can be
targeted at 350 seconds or greater [34].
Although platelets are important for hemostasis, our
results using this ex vivo model suggest that impaired
platelet activation does not impact the effectiveness of
gelatin matrices and fibrin sealants incorporating the
use of thrombin. An explanation for this finding comes
from one of our assays used to monitor patient compli-
ance to therapy. A statistically significant difference at
the 5% level was detected using ADP activated whole
blood aggregometry which demonstrated that the clopi-
dogrel donors had defective platelet activation com-
pared to the control donors. This result also indicates
that the donors do not harbor the polymorphism in the
CYP2C19 gene that renders them poor clopidogrel re-
sponders because they do not aggregate in response to
ADP [35]. However, when thrombin was used as the
agonist, the average whole blood aggregometry results
for clopidrogel donors were similar to that for control
donors. Whole blood aggregometry is a well-established
Figure 7 Representative images of thrombin based gelatin matrix clots acquired with FESEM. Control (A,B), clopidogrel (C,D); 10 μm scale
bars (A,C), 5 μm scale bars (B,D); Arrows: Gelatin (a), Fibrin (b), Red Blood Cells (c). No qualitative differences were observed in the fibrin structure
(porosity, fiber thickness, and branching) or the cellular accumulation around the gelatin granules including large numbers of trapped RBCs
between clopidogrel and control donor groups.
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found to correlate well with clinical outcome [36,37].
Therefore, these data demonstrate that thrombin can
initiate platelet aggregation in platelets that are unable
to respond to ADP due to clopidogrel blockade of the
P2Y12 receptor.
The high concentration of thrombin in the thrombin
based gelatin matrix and the fibrin sealant hemostats
provides a possible explanation for the lack of impact of
clopidogrel on their efficacy. The scientific literature
supports this conclusion in that thrombin is the most
potent activator of platelets and does so through a differ-
ent signal transduction pathway than ADP. Thrombin
activates platelets through the Par1/Par4 and GpI 7 re-
ceptors [38]. Once the signaling pathway is initiated, ac-
tivation propagates though PI3 kinase and GPIIb/IIIaFigure 8 Representative images of fibrin sealant clots acquired with F
Red Blood Cells (b). As seen in the images of the thrombin based gelatin mat
and control donor groups. The density of the fibrin structure seen compared
fibrinogen supplied by the fibrin sealant.leading to platelet aggregation and an increase in intra-
platelet calcium concentration [39]. Thus, thrombin may
not only play a central role in controlling bleeding,
but may also restore normal clot kinetics and strength
when used in combination with gelatin matrix and fibrin
sealant hemostats in patients who use prophylactic clo-
pidogrel as a platelet aggregation inhibitor. TEG analysis
of blood from donors using prophylactic clopidogrel
found no detectable impact on hemostasis stimulated by
either gelatin matrix or fibrin sealant hemostats which
contain thrombin when compared to the control donors.
This is consistent with the platelet aggregation results
and clot structure analysis.
Morphological characterization of clots formed when
thrombin based gelatin matrix and fibrin sealant hemostats
were mixed with donor blood supports the quantitativeESEM. Control (A), clopidogrel (B); 5 μm scale bars; Arrows: Fibrin (a),
rix clots, no qualitative differences were observed between clopidogrel
to the gelatin based hemostat clots may be due to the additional
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can be seen with FESEM based on the type of hemostat
used, the fibrin morphology and incorporation of red
blood cells between clots formed with clopidogrel donor
blood and those of the controls were similar. The clots
formed with fibrin sealant were similar to those seen previ-
ously [40,41] as well as those formed with the thrombin
based gelatin matrix hemostat [42]. Therefore, not only
does the use of thrombin attenuate the impact of clopido-
grel by initiating platelet activation while retaining normal
clot kinetics and strength, it also facilitates structurally
similar clots when used in combination with gelatin matrix
and fibrin sealant hemostats. However, this indicates only
the potential to form a structurally adequate clot in vivo
considering the artificial nature in which the clots were
created ex vivo.
Whole blood was selected for testing in that it more
closely reflects the conditions during surgical application
of the thrombin based gelatin matrix and fibrin sealant
hemostats, but there are considerations that must be ad-
dressed due to the presence of high concentration
thrombin in the hemostats. While thrombin is a potent
stimulator of platelets, it is also responsible for convert-
ing fibrinogen to fibrin, a reaction which also influences
whole blood platelet aggregometry and TEG results. In
the case of whole blood platelet aggregometry, the
thrombin concentration had to be reduced from the kit
concentration of 500 IU/ml to 1 IU/ml. For the purposes
of simplicity it was also referred to as to platelet aggre-
gometry even though a coagulation reaction was known
to have occurred. The same can be said for the TEG
assay in that the high concentration of thrombin in the
hemostats elicited the same reaction making it unlikely
to discern between coagulation and platelet aggregation
effects by this method. However, these tests were not de-
signed to imply a direct comparative basis for ADP stimu-
lated platelet aggregation to thrombin stimulated platelet
aggregation or to discern between coagulation and platelet
aggregation effects but to evaluate the effectiveness of the
hemostats when used with donor blood in which platelets
were inhibited by clopidogrel.
Based on these data, thrombin based gelatin matrices
and fibrin sealants are likely to be effective when used
during surgical procedures involving patients currently
on clopidogrel anti-platelet therapy. This is consistent
with recent clinical trial data demonstrating the effect-
iveness of a fibrin sealant based hemostat in patients on
platelet inhibitors [43]. Despite the clinically meaningful
results of this study, it was limited in scope and designed
to encourage additional clinical studies to verify the
basic findings of this work. The small patient numbers
are the main limitation of this exploratory study, redu-
cing the power of the statistical analysis to detect differ-
ences. Therefore, analysis focused on estimation ratherthan on hypothesis testing. Lack of clinical correlations
with this study’s TEG data is another obvious limitation.
However, other research using a rabbit bleeding model
to show that clopidogrel had no impact on the bleeding
rate in vivo [44] is consistent with results in human
blood presented in this paper.
This study also raises some interesting questions. In
the modern era of poly-pharmacy, the impact of multiple
medications such as SSRIs, SNRIs, platelet inhibitors,
thrombin inhibitors, and Vitamin K antagonists as well
as congenital deficiencies in hemostatic factors may
have unpredictable consequences on the regulation of
hemostasis. Consequently, surgical hemostats may have
to be carefully evaluated in the context of this growing
combinatorial complexity.Conclusion
The use of thrombin based gelatin matrices and fibrin
sealants initiated clot formation when mixed with blood
from donors on anti-platelet therapy that was similar to
that of control donor blood within the constraints of the
TEG assay. This study provided a basis for future inves-
tigation into the effectiveness of thrombin based hemo-
stats during surgical procedures involving patients on
anti-platelet therapy.
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